CATX Stock Forecast & Price Target

Perspective Therapeutics is compelling fundamentally because its 212Pb platform offers targeted alpha therapy with a potentially favorable safety profile, while early clinical data for VMT-α-NET and VMT01, including well-tolerated 2.5 and 5 mCi dose levels with no DLTs, support real therapeutic promise. The company’s decentralized manufacturing model and on-demand isotope generation reduce supply-chain risk, avoid the reactor and cyclotron constraints that burden other radiopharmaceuticals, and could create a durable operational advantage as the pipeline broadens into NET, melanoma, and FAP-positive solid tumors. With modeled peak U.S. sales of $2.7B for VMT-α-NET and $337M for VMT01, plus an expected ESMO update in October and Ph.III readiness targeted by end of ’26, the growth runway appears substantial.

Perspective Therapeutics is facing a weaker fundamental setup because its VMT-α-NET data, while clearly active, have not delivered the stronger efficacy needed to support a “blue sky” case, with cohort 2 ORR slipping to 33% from 43% and cohort 3 only reaching 50% at a higher dose. The safety profile remains comparatively clean, but the company now faces execution risk from a lengthy phase III path that may take 3+ years, plus manufacturing build-out costs and a competitive landscape where rivals are further along. With cash of about $200M only sufficient into late-’27 and fewer near-term catalysts, upside looks constrained even if the program ultimately remains biologically promising.